Piper Sandler initiated coverage of Caris Life Sciences (CAI) with a Neutral rating and $21 price target The firm says the company has built a “rare combination” of scientific leadership and financial sustainability in a sector where most competitors remain unprofitable. Piper believes Caris can grow total revenue near 20% over the next couple of years, but looks for therapy selection growth acceleration through salesforce expansion or new products before recommending the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAI:
- Caris Life Sciences price target lowered to $30 from $34 at Evercore ISI
- Caris Life Sciences launches Caris ChromoSeq tumor profiling assay
- Caris Life Sciences initiated with a Buy at Goldman Sachs
- Caris Life Sciences announces finalized Achieve 1 Study results
- Caris Life Sciences announces publication of study on GPSai algorithm